Abstract: A formulation for treating a patient with hepatocellular carcinoma is disclosed. The formulation comprises therapeutic agents in the form of nanoparticles containing one or more proteins or polysaccharides. The therapeutic agent is conjugated to an active targeting agent causing the formulation to preferentially segregate to the hepatocellular carcinoma tissue to release the therapeutic agents. Methods of treating hepatocellular carcinoma using the formulations are also disclosed.
Abstract: An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.
Type:
Grant
Filed:
July 9, 2015
Date of Patent:
January 17, 2017
Assignee:
Convatec Technologies Inc.
Inventors:
Steven L. Percival, Phillip G. Bowler, David Parsons
Abstract: The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.
Type:
Grant
Filed:
May 7, 2013
Date of Patent:
January 10, 2017
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Adrian Funke, Günter Meyer, Martina Smikalla, Andreas Meeners, Markus Wirges, Daniela Brock, Sarah Just, Peter Kleinebudde, Klaus Knop, Jochen Axel Zeitler, Rolf-Anton Boeggering
Abstract: The invention concerns the use of compounds with formula (I) R—N1-spermidine, or 1,4-butandiamin,N-(3-amino propyl)-N1-R, (I) H2N—(CH2)3—N1(R)—(CH2)4—NH2 either as such or in the form of a pharmaceutically acceptable derivative, such as an active ingredient in a cosmetic composition designed to promote hair pigmentation, particularly the pigmentation of the shaft, and a composition suitable to achieve said pigmentation effect and containing said active ingredient, either as such or in the form of a pharmaceutically acceptable derivative such as a salt, for topical administration.
Type:
Grant
Filed:
February 17, 2014
Date of Patent:
January 10, 2017
Assignee:
GIULIANI S.P.A.
Inventors:
Giammaria Giuliani, Ralf Paus, Anna Benedusi, Barbara Marzani, Sergio Baroni
Abstract: The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 ?m and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
Abstract: Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Abstract: An implant and a process for preparing such an implant are disclosed. The implant includes a mesh including a biodegradable polymeric coating having glass transition temperature of about 26° C. to about 36° C. The polymeric coating includes a first polymeric component including a lactone and a second polymeric component including a polyether. The first polymeric component is present in an amount from about 90% to about 99% of the polymeric coating and the second polymeric component is present in an amount from about 1% to about 10% of the polymeric coating.
Type:
Grant
Filed:
October 1, 2012
Date of Patent:
December 27, 2016
Assignees:
Covidien LP, Sofradim Production
Inventors:
Ahmad Robert Hadba, Olivier Lefranc, Jennifer Buffinton
Abstract: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.
Type:
Grant
Filed:
April 25, 2012
Date of Patent:
December 13, 2016
Assignee:
MERCK PATENT GMBH
Inventors:
Mario Maio, Eugenia Breininger, Karin Cabrera Perez, Ulrich Lang, Benjamin Peters, Thomas Puchert, Christoph Saal, Michael Schulz
Abstract: Antiperspirant/deodorant compositions have lower, or even zero amounts of aluminum and/or zirconium antiperspirant actives. A polymer having one or more anhydride and/or diacid moieties, such as succinic (maleic) anhydride and/or diacid. The antiperspirant/deodorant compositions comprise a polymer with a non-zero acid value and a cationic species, which may be a cationic polymer, cationic molecule, cation, and/or a cationic carrier. Product are formed for the antiperspirant/deodorant composition, as well as a method of treating perspiration.
Abstract: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose.
Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
Type:
Grant
Filed:
September 13, 2011
Date of Patent:
November 15, 2016
Assignee:
PHARMACYCLICS LLC
Inventors:
David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
Abstract: The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
Abstract: A biocide is formed by mixing at least one of ammonium sulfamate and ammonium carbamate with an aqueous solution of a hypochlorite oxidant at a molar ratio of ammonium to hypochlorite of at least 1:1. The biocide is useful in treating microbial or biofilm growth, pulp and paper process water, cooling tower water, waste water, reclaimed waste water, sludge, colloidal suspensions, irrigation water or a medium having a reducing capacity.
Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.
Type:
Grant
Filed:
July 3, 2013
Date of Patent:
September 27, 2016
Assignee:
Alfa Wassermann S.P.A
Inventors:
Giuseppe Claudio Viscomi, Laura Chelazzi, Fabrizia Grepioni, Dario Braga, Maddalena Kindt
Abstract: Manganese compositions effective in reducing Shiga toxin-induced toxicity in mammals infected with Shiga toxin-producing bacteria such as E. coli O157:H7 are described. Manganese compositions described herein can be combined with antibiotic therapy as manganese can block the toxic effects of Shiga toxin released from dying bacteria.
Type:
Grant
Filed:
January 18, 2012
Date of Patent:
September 13, 2016
Assignee:
Carnegie Mellon University
Inventors:
Adam D. Linstedt, Somshuvra Mukhopadhyay
Abstract: New compositions and methods are described for modulating the rate of conversion of ethylene bisdithiocarbamate fungicides, such as mancozeb, into ethylene bis-isothiocyanate sulfide (EBIS).
Type:
Grant
Filed:
December 27, 2013
Date of Patent:
August 30, 2016
Assignee:
Dow AgroSciences LLC
Inventors:
Min Zhao, Lei Liu, J. Todd Mathieson, Robert J. Ehr, Maria E. Rodriguez Rosas
Abstract: The present invention relates to the use of anthranilic acid diamide derivatives with heteroaromatic and heterocyclic substituents of formula (I) wherein R1, R2, R3, R4, R5, R6, n, A, Q have the meanings as given in the description—for controlling animal pests, such as insects and/or unwanted acarids and/or nematodes in transgenic crops and to methods particularly useful for controlling insects, and/or acarids and/or nematodes and/or increasing crop yield in those crops.
Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.
Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.
Type:
Grant
Filed:
August 21, 2014
Date of Patent:
August 2, 2016
Assignee:
Amrita Vishwa Vidyapeetham
Inventors:
Manzoor Koyakutty, Parwathy Chandran, Archana P. R., Shantikumar Nair
Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.